IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties - Sorbonne Université
Journal Articles Trends in Pharmacological Sciences Year : 2015

IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties

Abstract

Despite promising clinical trials, intravenous immunoglobulin (IVIg) therapy in relapsing–remitting multiple sclerosis (MS) has met with uncertainties that might be attributed to small patient cohorts, heterogeneity in the patients, dose of IVIg, or the duration and window of treatment.

Domains

Immunotherapy
Fichier principal
Vignette du fichier
Bayry_IVIg_for.pdf (472.2 Ko) Télécharger le fichier
Origin Files produced by the author(s)

HAL SU Administrateur  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-01155485

Submitted on : Tuesday, May 26, 2015-5:28:07 PM

Last modification on : Wednesday, October 2, 2024-6:58:43 PM

Long-term archiving on : Monday, April 24, 2017-3:38:50 PM

Download

Dates and versions

hal-01155485 , version 1 (26-05-2015)

Identifiers

Cite

Jagadeesh Bayry, Hans-Peter Hartung, Srini V Kaveri. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. Trends in Pharmacological Sciences, 2015, 36 (7), pp.419-421. ⟨10.1016/j.tips.2015.04.012⟩. ⟨hal-01155485⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM UNIV-PARIS7 UPMC EPHE CORDELIERS PSL SORBONNE-UNIVERSITE SU-SCIENCES UP-SANTE
126 View
532 Download

Altmetric

Share

More